Relay Therapeutics, Inc. Common Stock

RLAYNASDAQ • USD
18.74 USD
↘ 0.65 (3.35%)AT CLOSE (03:59 PM EDT)
18.60
↘ 0.14 (0.75%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
18.60
↘ 0.14 (0.75%)
🔴Market: CLOSED

Relay Therapeutics, Inc. Common Stock (RLAY) trades at $18.76 per share. There is a divergence between signals — technical indicators rate "Buy" but underlying fundamentals lean "Sell". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Furthermore, RLAY is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Oct 6, 2026.

Open?$19.50
High?$19.50
Low?$18.17
Prev. Close?$19.39
Volume?3.9M
Avg. Volume?3.3M
VWAP?$18.56
Rel. Volume?1.17x
Bid / Ask
Bid?$15.95 × 100
Ask?$21.76 × 100
Spread?$5.81
Midpoint?$18.86
Valuation & Ratios
Market Cap?4.2B
Shares Out?219.1M
Float?157.6M
Float %?71.9%
P/E Ratio?N/A
P/B Ratio?4.77
EPS?-$1.31
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Employees
192
Market Cap
4.2B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2020-07-16
Address
60 HAMPSHIRE STREET
CAMBRIDGE, MA 02139
Phone: 617-370-8837
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
17
Short Sent.?
10
Piotroski F-Score?0/9Weak
Altman Z-Score?29.82Safe
Confidence?55%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?28.23%Squeeze Risk
Short Interest?44.5M
Days to Cover?14.2
Free Float157.6M
Avg Daily Volume3.1M
Settlement Date2026-09-15
Financial Health
Current Ratio?18.27Strong
Quick Ratio?18.27Strong
Cash Ratio?2.39Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
38
4.77FAIR▾
P/S?
Peers
100
S&P
3
410.55HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-13.4CHEAP▾
EV/Sales?
Peers
100
S&P
3
398.84HIGH▾
Returns & Efficiency
ROE?
S&P
6
-32.2%WEAK▾
ROA?
S&P
3
-29.6%WEAK▾
Cash Flow & Enterprise
FCF?$-212205000
Enterprise Value?$4.1B
Fundamentals ratios updated end of day